Cargando…

Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with (“pseudo-randomized”) treatment allocation by the health insurance provider

INTRODUCTION: Despite a large number of trials, the role of bevacizumab (BEV) in the treatment of recurrent high-grade gliomas is still controversial. Evidence regarding an effect on overall survival in this context is ultimately inconclusive. At the Department of Radiation Oncology at Erlangen, Ger...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hofmann, Susanne, Schmidt, Manuel Alexander, Weissmann, Thomas, Eyüpoglu, Ilker, Strnad, Annedore, Semrau, Sabine, Fietkau, Rainer, Putz, Florian, Lettmaier, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316675/ https://www.ncbi.nlm.nih.gov/pubmed/32409944 http://dx.doi.org/10.1007/s11060-020-03533-5

Ejemplares similares

Transient Enlargement in Meningiomas Treated with Stereotactic Radiotherapy
por: Maksoud, Ziad, et al.
Publicado: (2022)

Oligometastatic head and neck cancer: Which patients benefit from radical local treatment of all tumour sites?
por: Weissmann, Thomas, et al.
Publicado: (2021)

Salivary gland carcinoma (SGC) with perineural spread and/or positive resection margin – high locoregional control rates after photon (chemo) radiotherapy - experience from a monocentric analysis
por: Haderlein, Marlen, et al.
Publicado: (2019)

High-grade salivary gland cancer: is surgery followed by radiotherapy an adequate treatment to reach tumor control? Results from a tertiary referral centre focussing on incidence and management of distant metastases
por: Freitag, Viola, et al.
Publicado: (2021)

Modulations in the Peripheral Immune System of Glioblastoma Patient Is Connected to Therapy and Tumor Progression—A Case Report from the IMMO-GLIO-01 Trial
por: Rühle, Paul F., et al.
Publicado: (2017)

Benchmarking ChatGPT-4 on a radiation oncology in-training exam and Red Journal Gray Zone cases: potentials and challenges for ai-assisted medical education and decision making in radiation oncology
por: Huang, Yixing, et al.
Publicado: (2023)

Adaptive radiotherapy and the dosimetric impact of inter- and intrafractional motion on the planning target volume for prostate cancer patients
por: Böckelmann, Felix, et al.
Publicado: (2020)

FSRT vs. SRS in Brain Metastases—Differences in Local Control and Radiation Necrosis—A Volumetric Study
por: Putz, Florian, et al.
Publicado: (2020)

Reduction of Elective Radiotherapy Treatment Volume in Definitive Treatment of Locally Advanced Head and Neck Cancer—Comparison of a Prospective Trial with a Revised Simulated Contouring Approach
por: Weissmann, Thomas, et al.
Publicado: (2021)

Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines
por: Rubner, Yvonne, et al.
Publicado: (2014)

Low- vs. high-dose radiotherapy in Graves’ ophthalmopathy: a retrospective comparison of long-term results
por: Weissmann, Thomas, et al.
Publicado: (2021)

Dose Reduction to the Swallowing Apparatus and the Salivary Glands by De-Intensification of Postoperative Radiotherapy in Patients with Head and Neck Cancer: First (Treatment Planning) Results of the Prospective Multicenter DIREKHT Trial
por: Haderlein, Marlen, et al.
Publicado: (2020)

Volumetric Regression in Brain Metastases After Stereotactic Radiotherapy: Time Course, Predictors, and Significance
por: Oft, Dominik, et al.
Publicado: (2021)

Bevacizumab in recurrent WHO grades II–III glioma
por: Annakib, Soufyan, et al.
Publicado: (2023)

Magnetic resonance imaging for brain stereotactic radiotherapy: A review of requirements and pitfalls
por: Putz, Florian, et al.
Publicado: (2020)

The Distribution of Pelvic Nodal Metastases in Prostate Cancer Reveals Potential to Advance and Personalize Pelvic Radiotherapy
por: Filimonova, Irina, et al.
Publicado: (2021)

COT-21 EFFECT OF BEVACIZUMAB FOR PEDIATRIC HIGH GRADE GLIOMA
por: Tsukamoto, Yoshihiro, et al.
Publicado: (2019)

Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges
por: Rahmathulla, Gazanfar, et al.
Publicado: (2013)

Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review
por: Kulinich, Daniel P., et al.
Publicado: (2021)

Deep learning for automatic head and neck lymph node level delineation provides expert-level accuracy
por: Weissmann, Thomas, et al.
Publicado: (2023)

Deep Learning and Registration-Based Mapping for Analyzing the Distribution of Nodal Metastases in Head and Neck Cancer Cohorts: Informing Optimal Radiotherapy Target Volume Design
por: Weissmann, Thomas, et al.
Publicado: (2023)

Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications
por: Li, Yi, et al.
Publicado: (2017)

Insurance Status Is Associated with Treatment Allocation and Outcomes after Subarachnoid Hemorrhage
por: Hobson, Charles, et al.
Publicado: (2014)

Low-Dose Radiotherapy Leads to a Systemic Anti-Inflammatory Shift in the Pre-Clinical K/BxN Serum Transfer Model and Reduces Osteoarthritic Pain in Patients
por: Weissmann, Thomas, et al.
Publicado: (2022)

Implementation of a dedicated 1.5 T MR scanner for radiotherapy treatment planning featuring a novel high-channel coil setup for brain imaging in treatment position
por: Mengling, Veit, et al.
Publicado: (2020)

Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial
por: Cohen, Adam L., et al.
Publicado: (2020)

Intraluminal brachytherapy in oesophageal cancer: defining its role and introducing the technique
por: Lettmaier, Sebastian, et al.
Publicado: (2014)

Should salvage surgery be considered for local recurrence after definitive chemoradiation in locally advanced non-small cell lung cancer?
por: Schreiner, Waldemar, et al.
Publicado: (2016)

Quantification of an External Motion Surrogate for Quality Assurance in Lung Cancer Radiation Therapy
por: Wölfelschneider, Jens, et al.
Publicado: (2014)

Performance of gimbal-based dynamic tumor tracking for treating liver carcinoma
por: Ziegler, Marc, et al.
Publicado: (2018)

An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals
por: Huylebrouck, M., et al.
Publicado: (2012)

Radiological Recurrence Patterns after Bevacizumab Treatment of Recurrent High-Grade Glioma: A Systematic Review and Meta-Analysis
por: Cho, Se Jin, et al.
Publicado: (2020)

A systematic review of the utility of amino acid PET in assessing treatment response to bevacizumab in recurrent high-grade glioma
por: Hughes, Kendall L, et al.
Publicado: (2021)

An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma
por: Chan, Joseph, et al.
Publicado: (2020)

Radio(chemo)therapy in anaplastic thyroid cancer—high locoregional but low distant control rates—a monocentric analysis of a tertiary referral center
por: Schmied, Matthias, et al.
Publicado: (2022)

Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes
por: Bovi, Joseph A., et al.
Publicado: (2020)

Targeted Therapy, Chemotherapy, Immunotherapy and Novel Treatment Options for Different Subtypes of Salivary Gland Cancer
por: Mueller, Sarina K., et al.
Publicado: (2022)

Bevacizumab for the Treatment of High-Grade Meningiomas: Is There New Evidence? [Letter]
por: da Silva, Vinicius Trindade Gomes, et al.
Publicado: (2022)

Low-dose radiotherapy of osteoarthritis: from biological findings to clinical effects—challenges for future studies
por: Weissmann, Thomas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tsb5f6usf331k1c7av3kc4l7hu